Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC_Apceth in Critical Limb Ischemia
NCT01351610Phase 2Completed
- Sponsor
- Apceth Biopharma
- Start
- Mar 2011
- Primary completion
- Oct 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MSC_Apceth in critical limb ischemia (CLI) (2 arms), sponsored by Apceth Biopharma. Primary endpoints: Collection of adverse events at 1 year, Safety laboratory values at 1 year and 2 more. Started Mar 2011; status: completed.
02
Drugs
MSC_Apceth
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT01351610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01351610.